ABSTRACT
This chapter includes four parts and covers initial regulatory responses to the new reproductive technologies as heralded by IVF divided between a centralization of regulation of reproduction and the particular handling of access, the newly independent embryo and oversight of medical practice and research. Key developments since 1990 are examined, including surrogacy, reproductive tourism, egg freezing and developments in the genetic handling of embryos, including pre-implantation screening and the development of stem cell lines for research. The final section briefly examines how regulation of NRTs and genetic engineering are influenced by financial interests.
